Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Tofacitinib |
Trade Name | Xeljanz |
Synonyms | Tasocitinib|CP-690550|CP-690,550 |
Drug Descriptions |
Xeljanz (tofacitinib) is a pan-JAK inhibitor, which decreases downstream signaling and potentially leads to reduced tumor cell growth (PMID: 26300391, PMID: 21106989). Xeljanz (tofacitinib) is FDA approved for rheumatoid arthritis (FDA.gov). |
DrugClasses | JAK Inhibitor (Pan) - ATP competitive 3 |
CAS Registry Number | 477600-75-2 |
NCIT ID | C95800 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Dexamethasone + Tofacitinib | Dexamethasone Tofacitinib | 1 | 0 |
LMB-100 + Tofacitinib | LMB-100 Tofacitinib | 0 | 1 |
Midostaurin + Tofacitinib | Midostaurin Tofacitinib | 2 | 0 |
Tofacitinib | Tofacitinib | 21 | 1 |